Last updated: April 23, 2026
AU2009255679: What Is Claimed, What’s in Scope, and How the Australia Patent Landscape Maps
What does AU2009255679 claim and how broad is its scope?
AU2009255679 is an Australian patent application published in the context of a drug patent family. The publicly indexed bibliographic record shows the application number, publication identifiers, applicant, and filing dates, but it does not provide claim text in the index page. Under patent scope analysis standards, claim interpretation must rely on the actual claim set (independent and dependent claims). In the absence of the full claim text for AU2009255679 from the available bibliographic record, a complete and accurate construction of scope and enforceable claim boundaries cannot be produced.
Which claim types typically define enforceable boundaries in this space?
For drug patents, enforceable scope usually comes from one or more of the following claim buckets:
- Product-by-composition (compound defined by structure, formula, salts, polymorphs)
- Product-by-process (composition made by a defined process)
- Use claims (compound/composition for a therapeutic indication, dosing regimen, patient subset)
- Method claims (method of treating a condition using a defined compound or regimen)
- Formulation claims (dosage form, excipients, release profile, particle attributes)
A precise mapping of which of these buckets AU2009255679 uses requires the claim text and the definition sections (where critical terms like “pharmaceutically acceptable,” “effective amount,” “comprising,” “about,” and parameter ranges are defined).
What is the patent landscape around AU2009255679 in Australia?
A landscape answer also requires family linkage and legal status for:
- the priority application and earliest filing date
- corresponding jurisdictions (EP, US, WO, etc.) that usually contain the same claim set
- Australia “same invention” coverage through divisional/grant publications
- third-party oppositions (if any) or prior-filed competitor families with overlapping chemical matter and indications
With only the Australia application number and without the underlying publication/claim text, the landscape cannot be constructed to the specificity required for high-stakes R&D or investment decisions (for example, identifying which competing filings cite or anticipate the claimed subject matter, or which family members cover formulation or method claims).
What would a defensible scope and claim-chart look like (based on the missing claim set)?
A claim chart for an Australian drug patent typically includes:
- Independent claim elements broken into limitations.
- Dependent claim dependencies to show fallback positions.
- Term construction from definitions and examples in the specification.
- Comparison targets: competitor compounds, salt forms, polymorphs, formulation types, and indication labels.
- Legal posture in Australia: grant status, estimated expiry, and any term adjustments.
Because the claim text is not available here, any attempt to list limitations, ranges, or therapeutic uses for AU2009255679 would be speculative.
Key information typically required to compute expiry and freedom-to-operate in Australia
To evaluate commercial exposure, the following inputs must be tied to the exact family:
- Priority date(s) and earliest priority
- Filing date in Australia
- Grant date (if granted) and any relevant legal events
- Term under Australian law (20 years from priority for standard patents, subject to adjustments)
- Any patent term extension where applicable
- Linkage to registered ARTG medicine and whether any supplementary protection exists through listed medicines
None of these can be concluded with precision from the data available for AU2009255679 in this context.
Key Takeaways
- AU2009255679 cannot be analyzed to an enforceable level (scope, claims, and landscape interactions) without the actual claim text and family/legal-status linkage.
- High-quality patent scope work depends on independent and dependent claim language plus the definitions used in the specification. Those are not present in the available index-level data here.
- A complete Australia landscape requires family identification and jurisdictional correspondences (WO/EP/US equivalents) to identify overlapping chemical matter, indications, and formulation coverage.
FAQs
-
Can I determine AU2009255679’s claim scope from the application number alone?
No. Scope is controlled by the claim text and definitions in the publication.
-
What documents are essential to map enforceable coverage for an Australian drug patent?
The published specification (including claims), the grant publication (if any), and family linkage to WO/EP/US where claim sets are often identical or provide interpretive context.
-
How is Australia patent expiry typically calculated for drug patents?
Usually from the earliest priority date (20-year term), subject to any adjustments and the patent’s legal status. This requires verified priority and status.
-
What makes a “landscape” for a drug patent actionable for R&D?
Identification of overlapping families, claim overlaps (compound vs formulation vs method), and whether competitors have earlier effective filings or distinct claim fallback positions.
-
What would a competitor review focus on for a drug patent like AU2009255679?
The exact claimed compound(s)/salts/polymorphs and the claimed therapeutic use, plus formulation/dosing parameters if present in the claims.
References
[1] IP Australia. Australian patent application AU2009255679 (bibliographic record).
